VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESGO 2021 | Durvalumab and oleclumab in patients with relapsed ovarian cancer

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the findings of a Phase II NSGO-OV-UMB1/ENGOT-OV30 study evaluating durvalumab and oleclumab, a monoclonal antibody against CD73, in patients with relapsed ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter